RxE2 Founder and CEO Gerald Finken on the Role and Value of Pharmacists in Clinical Research

Pharmacists demonstrate tremendous expertise in drug counseling and dispensation, so it seems undeniable that they should play a prominent role in clinical research. Surprisingly, their skill sets are rarely used in clinical trials. That’s why Founder and CEO Gerald Finken created RxE2, a community-based decentralized trial technology company spearheaded by pharmacists, offering primary stakeholders their…

How to boost excellence and innovation in clinical supply chains

By: Gerald E. Finken Originally posted on Linkedin In November 2021, McKinsey & Company published an interesting article on how to boost excellence and innovation in clinical supply chains that are relevant to today’s industry practices. What I found most compelling was how a best-in-class clinical supply chain could change and adapt to accommodate decentralized clinical trials (DCTs)…

The Impact of Decentralized Clinical Trials on the Investigational Drug Supply Chain: Making Clinical Supplies Patient-Centric

By: Gerald E. Finken The introduction of decentralized clinical trials (“DCTs”) into clinical research has, in recent years, focused on the use of technology and telehealth to improve the clinical trial experience for patients. The proponents of the DCT model have heralded it, and rightly so, with improving study recruitment, providing better patient diversity, and…

Everyone Everywhere with Gerald Finken | Episode 1

Join us Live with our guest Tripp Logan, COO ESPhA, for a conversation on State Pharmacy Regulations and Decentralized Trials. The Enhanced Service Pharmacy Alliance (ESPhA) is the pharmacy industry’s only next-generation pharmacy service consulting firm. ESPhA’s mission is to foster an alliance of quality-driven, patient-focused pharmacists, pharmacies, consultants, vendors, and payer partners to collaborate…